P53 gene alterations in differentiated thyroid cancers

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Thyroid cancer encompasses several subtypes, including papillary (PTC), follicular (FTC), and medullary (MTC).
• The role of p53 gene alterations in thyroid tumorigenesis is an area of ongoing investigation.
• Previous studies suggested p53 alterations are primarily associated with advanced or undifferentiated thyroid cancer stages.

Purpose of the Study:

• To investigate the frequency and types of p53 gene alterations in human thyroid cancers.
• To determine the association of p53 alterations with different thyroid cancer subtypes and clinical stages.
• To clarify the role of p53 alterations in differentiated versus undifferentiated thyroid cancer.

Main Methods:

• Analysis of 22 human thyroid cancer samples (PTC, FTC, MTC).
• Polymerase Chain Reaction - Single Strand Conformation Polymorphism (PCR-SSCP) for mutation detection.
• Immunohistochemistry for p53 protein expression and mutation analysis.

Main Results:

• Four deletions and three mutations in the p53 gene were detected across the analyzed thyroid cancer samples.
• Deletions involved exons 1, 2-3, and 5-6 in papillary thyroid cancers.
• Mutations were found in exons 2-3 (medullary thyroid cancers) and exons 8-9 (papillary thyroid cancer).
• p53 alterations were observed in recurrent tumors and tumors that developed into cell lines.
• Immunohistochemistry revealed p53 mutations in differentiated areas of papillary thyroid cancers, occurring from stage T1 to T4.

Conclusions:

• p53 gene alterations are present in various human thyroid cancer subtypes, including differentiated papillary thyroid cancers.
• The findings indicate that p53 mutations are frequent events in differentiated papillary thyroid cancers, contrary to previous literature.
• These alterations occur across multiple clinical stages (T1-T4), suggesting an earlier role in thyroid cancer development than previously recognized.